New insulin analogues

Diabetes Technology and Therapeutics

Volumn 7, Issue 5, 2005, Pages 813-817

  Garg, Satish K ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

CELL FUNCTION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG USE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PREDICTION; PREVALENCE; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN;

EID: 27644544000     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2005.7.813     Document Type: Conference Paper

References (17)

1. Wallace TM, Matthews DR: Poor glycaemic control in type 2 diabetes: A conspiracy of disease, suboptimal therapy and attitude. QJM 2000;93:369-374.
2. Brown JB, Nichols GA: Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care 2003;9:213-217.
3. Lebovitz HE: Diabetes Rev 1999;7:139-153.
4. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993;16:21-31.
5. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995;18:1113-1123.
6. Niskanen L, Jensen LE, Rastam J, Nygaard-Pedersen L, Erichsen K, Vora JP: Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004;26:531-540.
7. Roach, Koledova E, Metcalfe S, Hultman C, Milicevic Z; Romania/Russia Mix25 Study Group: Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. Clin Ther 2001;23:1732-1744.
8. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S: Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000;37:41-46.
9. Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997;157:1249-1255.
10. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK: The impact of the Diabetes Control and Complications Trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001;24:430-434.
11. Overmann H, Heinemann L: Injection-meal interval: Recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137-142.
12. Lepore et al.: Diabetes 1999;48(Suppl 1):A97.
13. Garg SK et al.: ADA Scientific Sessions 2004, Abstracts 529, 530.
14. Garg SK, Rosenstock J, Ways K: Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005;11:11-17.
15. Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP: Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004;66:49-56.
16. Pieber et al.: Diabetes 2002;51(Suppl 2):A53.
17. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 2004;26:1081-1087.